Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study.
Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Festa S, et al. Among authors: allocca m. United European Gastroenterol J. 2021 May;9(4):507-516. doi: 10.1177/2050640620977405. Epub 2021 Feb 16. United European Gastroenterol J. 2021. PMID: 33259773 Free PMC article.
Golimumab: clinical update on its use for ulcerative colitis.
Gilardi D, Fiorino G, Allocca M, Bravatà I, Danese S. Gilardi D, et al. Among authors: allocca m. Drugs Today (Barc). 2015 Mar;51(3):171-84. doi: 10.1358/dot.2015.51.3.2298240. Drugs Today (Barc). 2015. PMID: 25876561 Review.
Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?
Allocca M, Fiorino G, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L, Danese S. Allocca M, et al. Curr Drug Targets. 2018;19(7):748-756. doi: 10.2174/1389450117666160527142719. Curr Drug Targets. 2018. PMID: 27231106 Review.
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Kopylov U, et al. Among authors: allocca m. Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155. Inflamm Bowel Dis. 2018. PMID: 29788318
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. Allocca M, et al. Expert Opin Investig Drugs. 2018 Jul;27(7):623-629. doi: 10.1080/13543784.2018.1494722. Epub 2018 Jul 16. Expert Opin Investig Drugs. 2018. PMID: 29985060 Review.
Can IL-23 be a good target for ulcerative colitis?
Allocca M, Furfaro F, Fiorino G, Gilardi D, D'Alessio S, Danese S. Allocca M, et al. Best Pract Res Clin Gastroenterol. 2018 Feb-Apr;32-33:95-102. doi: 10.1016/j.bpg.2018.05.016. Epub 2018 May 23. Best Pract Res Clin Gastroenterol. 2018. PMID: 30060945 Review.
197 results